KRAS and neoplasm: Accordingly, the infusion of CD8+ T cells targeting mutated KRAS variants could be effective anti‐tumor effects in human metastatic malignancies that expressed HLA‐C*08:02 and KRASG12D, including CRC.[18, 94] As mentioned, infiltrated neoantigen‐specific CD8+ T cells in the TME can inhibit tumor growth.